Cargando…

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea

BACKGROUND: Complex cutaneous and muco-cutaneous leishmaniasis (CL and MCL) often requires systemic therapy. Liposomal amphotericin B (L-AmB) has a strong potential for a solid clinical benefit in this indication. METHODS: We conducted a retrospective analysis of data from a French centralized refer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guery, Romain, Henry, Benoit, Martin-Blondel, Guillaume, Rouzaud, Claire, Cordoliani, Florence, Harms, Gundel, Gangneux, Jean-Pierre, Foulet, Françoise, Bourrat, Emmanuelle, Baccard, Michel, Morizot, Gloria, Consigny, Paul-Henri, Berry, Antoine, Blum, Johannes, Lortholary, Olivier, Buffet, Pierre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714383/ https://www.ncbi.nlm.nih.gov/pubmed/29155816 http://dx.doi.org/10.1371/journal.pntd.0006094

Ejemplares similares

Self-application of aminoglycoside-based creams to treat cutaneous leishmaniasis in travelers
por: Mouri, Oussama, et al.
Publicado: (2023)

Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy
por: Darcis, Gilles, et al.
Publicado: (2017)

Recurrent American Cutaneous Leishmaniasis
por: Gangneux, Jean-Pierre, et al.
Publicado: (2007)

Hoarseness as the Presenting Symptom of Visceral Leishmaniasis with Muco-Cutaneous Lesions: A Case Report
por: MORTAZAVI, Hossein, et al.
Publicado: (2015)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B
por: Morizot, Gloria, et al.
Publicado: (2016)

Efficacy of Intralesional Amphotericin B for the Treatment of Cutaneous Leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2014)

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
por: Ubals, Maria, et al.
Publicado: (2021)

Muco-cutaneous manifestations in HIV infection/AIDS
por: Benea, Vasile, et al.
Publicado: (2014)

Optimization of Topical Therapy for Leishmania major Localized Cutaneous Leishmaniasis Using a Reliable C57BL/6 Model
por: Lecoeur, Hervé, et al.
Publicado: (2007)

Outbreak of Leishmania braziliensis Cutaneous Leishmaniasis, Saül, French Guiana
por: Martin-Blondel, Guillaume, et al.
Publicado: (2015)

Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis
por: Riezk, Alaa, et al.
Publicado: (2020)

Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
por: Jaafari, Mahmoud Reza, et al.
Publicado: (2019)

Methodology of Clinical Trials Aimed at Assessing Interventions for Cutaneous Leishmaniasis
por: Olliaro, Piero, et al.
Publicado: (2013)

Mixed muco-cutaneous pemphigoid: Clinical and immunological features of 15 cases
por: Janela, Raphaël, et al.
Publicado: (2023)

962. Cutaneous Leishmaniasis: Investigating Skin Drug Levels to Optimize Liposomal Amphotericin Dosing
por: Aronson, Naomi E, et al.
Publicado: (2018)

Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of Cutaneous leishmaniasis
por: Anjum, Adnan, et al.
Publicado: (2023)

Clinical diversity and treatment results in Tegumentary Leishmaniasis: A European clinical report in 459 patients
por: Guery, Romain, et al.
Publicado: (2021)

Rhinophyma-Like Cutaneous Leishmaniasis due to Leishmania aethiopica Treated Successfully with Liposomal Amphotericin B
por: Kirchberger, Michael Constantin, et al.
Publicado: (2019)

Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis
por: Shirzadi, Mohammad Reza
Publicado: (2019)

Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
por: Kosaka, Atsushi, et al.
Publicado: (2020)

Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles
por: Sousa-Batista, Ariane J., et al.
Publicado: (2019)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
por: Ramos, Guilherme S., et al.
Publicado: (2022)

Cutaneous leishmaniasis mimicking cutaneous lymphoma
por: Pires, Carla Andréa Avelar, et al.
Publicado: (2019)

Optimization of multiple muco-cutaneous site sampling method for screening MRSA colonization in ICU
por: Datta, Priya, et al.
Publicado: (2013)

Tumor-Infiltrating CD8+ Lymphocytes Effect on Clinical Outcome of Muco-Cutaneous Melanoma
por: Rahbar, Mahtab, et al.
Publicado: (2015)

Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases – A systematic review
por: Strietzel, Frank P., et al.
Publicado: (2019)

Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis
por: Layegh, Pouran, et al.
Publicado: (2011)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome(®) and AmBisome(®) in murine cutaneous leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate
por: Senchyna, A., et al.
Publicado: (2020)

Intravenous Liposomal Amphotericin B Efficacy and Safety for Cutaneous and Mucosal Leishmaniasis: A Systematic Review and Meta-analysis
por: Chivinski, Jeffrey, et al.
Publicado: (2023)

Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13–15 June, 2006
por: Modabber, Farrokh, et al.
Publicado: (2007)

Recurrent cutaneous leishmaniasis*
por: Gomes, Ciro Martins, et al.
Publicado: (2013)

Zosteriform cutaneous leishmaniasis
por: Tin, Sim Sai, et al.
Publicado: (2014)

Biomarkers of Cutaneous Leishmaniasis
por: Bahrami, Fariborz, et al.
Publicado: (2018)

Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
por: Caridha, Diana, et al.
Publicado: (2019)

Comparison of Efficacy of Two Different Concentrations of Intralesional Amphotericin B in the Treatment of Cutaneous Leishmaniasis; A Randomized Controlled Trial
por: Goswami, Pooja, et al.
Publicado: (2019)

Intravenous liposomal amphotericin B efficacy and safety for cutaneous and mucosal leishmaniasis: a systematic review and meta-analysis protocol
por: Naeem, Faheel, et al.
Publicado: (2021)

Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature
por: Paolino, Giovanni, et al.
Publicado: (2023)

WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled Study
por: Ben Salah, Afif, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_v105dgq819bhtkj4md141lfgvc